Development and Validation of a Machine-Learning Model to Predict Early Recurrence of Intrahepatic Cholangiocarcinoma.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 17 02 2023
accepted: 26 04 2023
medline: 11 8 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: ppublish

Résumé

The high incidence of early recurrence after hepatectomy for intrahepatic cholangiocarcinoma (ICC) has a detrimental effect on overall survival (OS). Machine-learning models may improve the accuracy of outcome prediction for malignancies. Patients who underwent curative-intent hepatectomy for ICC were identified using an international database. Three machine-learning models were trained to predict early recurrence (< 12 months after hepatectomy) using 14 clinicopathologic characteristics. The area under the receiver operating curve (AUC) was used to assess their discrimination ability. In this study, 536 patients were randomly assigned to training (n = 376, 70.1%) and testing (n = 160, 29.9%) cohorts. Overall, 270 (50.4%) patients experienced early recurrence (training: n = 150 [50.3%] vs testing: n = 81 [50.6%]), with a median tumor burden score (TBS) of 5.6 (training: 5.8 [interquartile range {IQR}, 4.1-8.1] vs testing: 5.5 [IQR, 3.7-7.9]) and metastatic/undetermined nodes (N1/NX) in the majority of the patients (training: n = 282 [75.0%] vs testing n = 118 [73.8%]). Among the three different machine-learning algorithms, random forest (RF) demonstrated the highest discrimination in the training/testing cohorts (RF [AUC, 0.904/0.779] vs support vector machine [AUC, 0.671/0.746] vs logistic regression [AUC, 0.668/0.745]). The five most influential variables in the final model were TBS, perineural invasion, microvascular invasion, CA 19-9 lower than 200 U/mL, and N1/NX disease. The RF model successfully stratified OS relative to the risk of early recurrence. Machine-learning prediction of early recurrence after ICC resection may inform tailored counseling, treatment, and recommendations. An easy-to-use calculator based on the RF model was developed and made available online.

Sections du résumé

BACKGROUND BACKGROUND
The high incidence of early recurrence after hepatectomy for intrahepatic cholangiocarcinoma (ICC) has a detrimental effect on overall survival (OS). Machine-learning models may improve the accuracy of outcome prediction for malignancies.
METHODS METHODS
Patients who underwent curative-intent hepatectomy for ICC were identified using an international database. Three machine-learning models were trained to predict early recurrence (< 12 months after hepatectomy) using 14 clinicopathologic characteristics. The area under the receiver operating curve (AUC) was used to assess their discrimination ability.
RESULTS RESULTS
In this study, 536 patients were randomly assigned to training (n = 376, 70.1%) and testing (n = 160, 29.9%) cohorts. Overall, 270 (50.4%) patients experienced early recurrence (training: n = 150 [50.3%] vs testing: n = 81 [50.6%]), with a median tumor burden score (TBS) of 5.6 (training: 5.8 [interquartile range {IQR}, 4.1-8.1] vs testing: 5.5 [IQR, 3.7-7.9]) and metastatic/undetermined nodes (N1/NX) in the majority of the patients (training: n = 282 [75.0%] vs testing n = 118 [73.8%]). Among the three different machine-learning algorithms, random forest (RF) demonstrated the highest discrimination in the training/testing cohorts (RF [AUC, 0.904/0.779] vs support vector machine [AUC, 0.671/0.746] vs logistic regression [AUC, 0.668/0.745]). The five most influential variables in the final model were TBS, perineural invasion, microvascular invasion, CA 19-9 lower than 200 U/mL, and N1/NX disease. The RF model successfully stratified OS relative to the risk of early recurrence.
CONCLUSIONS CONCLUSIONS
Machine-learning prediction of early recurrence after ICC resection may inform tailored counseling, treatment, and recommendations. An easy-to-use calculator based on the RF model was developed and made available online.

Identifiants

pubmed: 37210452
doi: 10.1245/s10434-023-13636-8
pii: 10.1245/s10434-023-13636-8
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5406-5415

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023. Society of Surgical Oncology.

Références

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660 pubmed: 33538338
Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155:823–31.
doi: 10.1001/jamasurg.2020.1973 pubmed: 32639548
Spolverato G, Glavas D, Hewitt DB, et al. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother. 2022;23:473–81.
doi: 10.1080/14656566.2021.2020250 pubmed: 34964678
Choi WJ, Williams PJ, Claasen M, et al. Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection. Ann Surg Oncol. 2022;29:4337–53.
doi: 10.1245/s10434-022-11463-x
Tsilimigras DI, Mehta R, Moris D, et al. A machine-based approach to preoperatively identify patients with the most and least benefit associated with resection for intrahepatic cholangiocarcinoma: an international multi-institutional analysis of 1146 patients. Ann Surg Oncol. 2020;27:1110–9.
doi: 10.1245/s10434-019-08067-3 pubmed: 31728792
Li M, Du M, Cong H, et al. Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma. Hepatol Res. 2021;51:102–15.
doi: 10.1111/hepr.13580 pubmed: 33037855
Wu ZY, Shen W, Yue JQ, et al. Combining immunoscore with clinicopathologic features in cholangiocarcinoma: an influential prognostic nomogram. Onco Targets Ther. 2020;13:11359–76.
doi: 10.2147/OTT.S274754 pubmed: 33192071 pmcid: 7654544
Cheng Z, Lei Z, Jin X, et al. Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis. J Gastrointest Oncol. 2021;12:819–30.
doi: 10.21037/jgo-20-443 pubmed: 34012669 pmcid: 8107590
Kaibori M, Yoshii K, Kashiwabara K, et al. Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey. Hepatol Res. 2021;51:890–901.
doi: 10.1111/hepr.13676 pubmed: 34041804
Krenzien F, Nevermann N, Krombholz A, et al. Treatment of intrahepatic cholangiocarcinoma: a multidisciplinary approach. Cancers Basel. 2022;14:362.
doi: 10.3390/cancers14020362 pubmed: 35053523 pmcid: 8773654
Wei T, Zhang XF, He J, et al. Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. Br J Surg. 2022;109:610–6.
doi: 10.1093/bjs/znac098 pubmed: 35511599
Buettner S, Galjart B, van Vugt JLA, et al. Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017;116:1085–95.
doi: 10.1002/jso.24759 pubmed: 28703880
Langella S, Russolillo N, Ossola P, et al. Recurrence after curative resection for intrahepatic cholangiocarcinoma: how to predict the chance of repeat hepatectomy. J Clin Med. 2021;10:2820.
doi: 10.3390/jcm10132820 pubmed: 34206799 pmcid: 8269164
Alaimo L, Moazzam Z, Brown ZJ, et al. Application of hazard function to investigate recurrence of intrahepatic cholangiocarcinoma after curative-intent liver resection: a novel approach to characterize recurrence. Ann Surg Oncol. 2022;30:1340–9.
doi: 10.1245/s10434-022-12463-7 pubmed: 36029379
Li Q, Zhang J, Chen C, et al. A nomogram model to predict early recurrence of patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy guidance: a multi-institutional analysis. Front Oncol. 2022;12:896764.
doi: 10.3389/fonc.2022.896764 pubmed: 35814440 pmcid: 9259984
Song Y, Cai M, Li Y, et al. The focus clinical research in intrahepatic cholangiocarcinoma. Eur J Med Res. 2022;27:116.
doi: 10.1186/s40001-022-00741-9 pubmed: 35820926 pmcid: 9277934
Tan YG, Fang AHS, Lim JKS, et al. Incorporating artificial intelligence in urology: supervised machine-learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy. Prostate. 2022;82:298–305.
doi: 10.1002/pros.24272 pubmed: 34855228
Rahman SA, Walker RC, Maynard N, et al. The AUGIS survival predictor: prediction of long-term and conditional survival after esophagectomy using Random Survival Forests. Ann Surg. 2023;277(2):267–74.
Kudo SE, Ichimasa K, Villard B, et al. Artificial intelligence system to determine risk of T1 colorectal cancer metastasis to lymph node. Gastroenterology. 2021;160:1075-84.e2.
doi: 10.1053/j.gastro.2020.09.027 pubmed: 32979355
Ichimasa K, Kudo SE, Mori Y, et al. Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer. Endoscopy. 2018;50:230–40.
doi: 10.1055/s-0043-122385 pubmed: 29272905
Amin MBES, Greene FL, et al. American Joint Committee on Cancer. Berlin: Springer; 2017.
Sasaki K, Morioka D, Conci S, et al. The tumor burden score: a new “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267:132–41.
doi: 10.1097/SLA.0000000000002064 pubmed: 27763897
Pang YY. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000; 2:333–9. HPB Oxford. 2002;4:99; author reply 99–100.
Liang W, Xu L, Yang P, et al. Novel nomogram for preoperative prediction of early recurrence in intrahepatic cholangiocarcinoma. Front Oncol. 2018;8:360.
doi: 10.3389/fonc.2018.00360 pubmed: 30234019 pmcid: 6131601
Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1-73.
doi: 10.7326/M14-0698 pubmed: 25560730
Wilson A, Winner M, Yahanda A, et al. Factors associated with decisional regret among patients undergoing major thoracic and abdominal operations. Surgery. 2017;161:1058–66.
doi: 10.1016/j.surg.2016.10.028 pubmed: 27993362
Winner M, Wilson A, Yahanda A, et al. Cancer surgeons’ attitudes and practices about discussing the chance of operative “cure.” Surgery. 2016;160:1619–27.
doi: 10.1016/j.surg.2016.06.009 pubmed: 27499144
Bagante F, Spolverato G, Cucchetti A, et al. Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: a regret-based decision curves analysis. Surgery. 2016;160:106–17.
doi: 10.1016/j.surg.2016.01.023 pubmed: 27046702
Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40:2048–57.
doi: 10.1200/JCO.21.02568 pubmed: 35316080
Akateh C, Ejaz AM, Pawlik TM, et al. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol. 2020;12:693–708.
doi: 10.4254/wjh.v12.i10.693 pubmed: 33200010 pmcid: 7643214
Buettner S, Koerkamp BG, Ejaz A, et al. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients: a multi-institutional analysis. J Surg Oncol. 2017;115:312–8.
doi: 10.1002/jso.24524 pubmed: 28105651
Li Z, Yuan L, Zhang C, et al. A novel prognostic scoring system of intrahepatic cholangiocarcinoma with machine learning basing on real-world data. Front Oncol. 2020;10:576901.
doi: 10.3389/fonc.2020.576901 pubmed: 33552957
Li H, Liu R, Qiu H, et al. Tumor burden score stratifies prognosis of patients with intrahepatic cholangiocarcinoma after hepatic resection: a retrospective, multi-institutional study. Front Oncol. 2022;12:829407.
doi: 10.3389/fonc.2022.829407 pubmed: 35330712 pmcid: 8940520
Zhang Z, Zhou Y, Hu K, et al. Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study. BMC Cancer. 2020;20:270.
doi: 10.1186/s12885-020-06781-w pubmed: 32228636 pmcid: 7106692
Nassar A, Tzedakis S, Sindayigaya R, et al. Factors of early recurrence after resection for intrahepatic cholangiocarcinoma. World J Surg. 2022;46:2459–67.
doi: 10.1007/s00268-022-06655-1 pubmed: 35819486
Zhang XF, Chakedis J, Bagante F, et al. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. Br J Surg. 2018;105:857–66.
doi: 10.1002/bjs.10827 pubmed: 29656380
Acher AW, Paro A, Elfadaly A, et al. Intrahepatic cholangiocarcinoma: a summative review of biomarkers and targeted therapies. Cancers Basel. 2021;13:5169.
doi: 10.3390/cancers13205169 pubmed: 34680318 pmcid: 8533913

Auteurs

Laura Alaimo (L)

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Department of Surgery, University of Verona, Verona, Italy.

Henrique A Lima (HA)

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Zorays Moazzam (Z)

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Yutaka Endo (Y)

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Jason Yang (J)

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Andrea Ruzzenente (A)

Department of Surgery, University of Verona, Verona, Italy.

Alfredo Guglielmi (A)

Department of Surgery, University of Verona, Verona, Italy.

Luca Aldrighetti (L)

Department of Surgery, Ospedale San Raffaele, Milan, Italy.

Matthew Weiss (M)

Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.

Todd W Bauer (TW)

Department of Surgery, University of Virginia, Charlottesville, VA, USA.

Sorin Alexandrescu (S)

Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.

George A Poultsides (GA)

Department of Surgery, Stanford University, Stanford, CA, USA.

Shishir K Maithel (SK)

Department of Surgery, Emory University, Atlanta, GA, USA.

Hugo P Marques (HP)

Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal.

Guillaume Martel (G)

Department of Surgery, University of Ottawa, Ottawa, ON, Canada.

Carlo Pulitano (C)

Department of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.

Feng Shen (F)

Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.

François Cauchy (F)

Department of Hepatobiliopancreatic Surgery and Liver Transplantation, AP-HP, Beaujon Hospital, Clichy, France.

Bas Groot Koerkamp (BG)

Department of Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Itaru Endo (I)

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.

Minoru Kitago (M)

Department of Surgery, Keio University, Tokyo, Japan.

Timothy M Pawlik (TM)

Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu.
Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH